Multicentric Castleman Disease and Systemic Lupus Erythematosus Phenotype in a Boy With Klinefelter Syndrome: Long-term Disease Stabilization With Interferon Therapy

Simkó, Róbert; Nagy, Kálmán; Lombay, B; Kiss, Ákos; Minik, K; Lukács, Valéria; Vámosi, Ildikó

doi:10.1097/00043426-200003000-00021

Cited by 21 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 Treatment with interferon-␣ or with the anti-CD20 monoclonal antibody rituximab (Rituxan; Hoffman-La Roche, Basel, Switzerland) has resulted in durable clinical remission of the disease; however, these findings are based on a small number of patients. 11,12 Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biologic activities, including support of hematopoiesis and regulation of immune responses. 13 Dysregulated overproduction of IL-6 from germinal center B cells is implicated in the pathogenesis of plasma-cell-type Castleman disease.…”

Section: Introductionmentioning

confidence: 99%

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Nishimoto

Kanakura

Aozasa

et al. 2005

Blood

668

493

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Nishimoto

Kanakura

Aozasa

et al. 2005

Blood

668

493

View full text Add to dashboard Cite

show abstract

“…CD, which also refers to giant lymph node hyperplasia, is described as an atypical lymphoproliferation disorder that may present with or without systemic symptoms. Some reports have showed that multicentric CD has a close association with several autoimmune conditions such as thrombocytic thrombocytopenic purpura, rheumatoid arthritis, pemphigus vulgaris and membranous nephropathy [2,3]. In this report, we present a patient with SLE combined with CD morphology.…”

Section: Introductionmentioning

confidence: 81%

A case report of systemic lupus erythematosus combined with Castleman’s disease and literature review

Xia

Chen

et al. 2010

Rheumatol Int

View full text Add to dashboard Cite

Although lymph node enlargement is common in active systemic lupus erythematosus (SLE), lymph node examination is frequently ignored in the diagnosis of SLE. Clinical presentation and abnormal laboratory findings are often sufficient for SLE diagnosis, not to mention that the specific histological finding of lymph node necrosis in SLE is rarely seen, and the follicular hyperplasia is usually considered as nonspecific. However, since the late 1990s, a few cases of SLE lymphadenopathy have been reported exhibiting a Castleman's disease (CD) morphology, which was discovered in lymph node biopsies. Here we report a similar case of SLE combined with CD in a 23-year-old girl who displayed systemic symptoms, including systemic lymphadenopathy and abnormal laboratory findings indicating the active phase of SLE. A biopsy of neck lymphnodes showed histopathological features of CD. The patient responded very well to the prednisolone treatment. Based on the related literature review, we would like to stress the possibility of CD in patients with SLE lymphadenopathy.

show abstract

“…In the 1990s, systemic treatment for MCD included chemotherapy based on regimens for lymphoma such as cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) (1)(2)(3)(4). Treatment with a monoclonal antibody diNephrology Center, Toranomon Hospital Kajigaya, Japan and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan (12).…”

Section: Introductionmentioning

confidence: 99%

Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years

et al. 2015

View full text Add to dashboard Cite

We herein report the long-term outcome (30 years) of a human immunodeticiency virus-and human herpesvirus 8-negative Japanese man who was diagnosed to have multicentric Castleman disease (MCD) of the plasmacytic type after investigation of generalized lymphadenopathy at 34 of age in 1983. He received chemotherapy based on lymphoma regimens (combinations of prednisolone, vincristine, vindesine, cyclophosphamide, etoposide, melphalan, and ranimustine, etc.) for over 20 years. Although the systemic lymphadenopathy resolved, AA amyloidosis-related nephropathy occurred, with a serum creatinine (Cre) level of 0.9 mg/ dL and urinary protein excretion (UP) of 7.5 g daily. Rituximab was started, but Cre increased to 2.6 mg/dL in 2010 and UP was unchanged. Therefore, treatment with tocilizmab was started. As a result, his hypergammaglobulinemia was well controlled, C-reactive protein became normal, UP decreased to 3.5 g daily, and Cre remained at 2.5 mg/dL in 2013. When AA amyloid nephropathy occurred after long-term chemotherapy, lituximab could not control it, but tocilizmab stopped the progression of nephropathy. This case suggests that MCD and AA amyloidosis may both have a close relationship to the overproduction of interleukin-6.

show abstract

Multicentric Castleman Disease and Systemic Lupus Erythematosus Phenotype in a Boy With Klinefelter Syndrome: Long-term Disease Stabilization With Interferon Therapy

Cited by 21 publications

References 20 publications

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

A case report of systemic lupus erythematosus combined with Castleman’s disease and literature review

Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years

Contact Info

Product

Resources

About